Editas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($0.23), $0.36 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $60.04 million versus the consensus estimate of $3.7 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.